Brigatinib - ARIAD Pharmaceuticals

Drug Profile

Brigatinib - ARIAD Pharmaceuticals

Alternative Names: ALUNBRIG; AP-26113

Latest Information Update: 19 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ARIAD Pharmaceuticals
  • Class Antineoplastics; Diamines; Piperazines; Piperidines; Pyrimidines; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; Epidermal growth factor receptor antagonists; ROS1-protein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Non-small cell lung cancer
  • No development reported Lymphoma; Neuroblastoma

Most Recent Events

  • 16 Oct 2017 Updated safety and efficacy data from the phase II ALTA trial in Non-small cell lung cancer released by Takeda
  • 03 Oct 2017 US FDA approves sNDA for 180 mg tablet formulation of Brigatinib for the treatment of Non-small cell lung cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater)
  • 02 Jun 2017 Updated efficacy and adverse events data from the phase II ALTA trial in Non-small-cell lung cancer presented at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top